GB

Roger Crystal

This inventor holds 0 USPTO granted patents, plus 2 CIPO patents.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Roger Crystal. Retrieved from https://idiyas.com/inventor/roger-crystal-pg3iii7c

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

 

Average Co-Inventor Count = 1.0

ph-index = 1


Loading Chart...

Title: Roger Crystal - Innovator in Nasal Drug Delivery

Introduction

Roger Crystal is a notable inventor based in Great Britain, recognized for his contributions to the field of pharmaceutical compositions. He has developed innovative solutions aimed at addressing critical health issues, particularly in the realm of opioid overdose treatment.

Latest Patents

Roger Crystal holds a patent for "Nasal Naloxone Compositions And Devices." This invention involves drug products specifically adapted for nasal delivery. The products comprise a pre-primed device filled with a pharmaceutical composition that includes an opioid receptor antagonist. The methods associated with this invention provide effective treatment for opioid overdose or its symptoms.

Career Highlights

Roger Crystal is currently associated with Opiant Pharmaceuticals, Inc., where he continues to work on advancing drug delivery systems. His expertise in the field has positioned him as a key player in developing innovative solutions for public health challenges.

Collaborations

Roger collaborates with Michael Brenner Weiss, contributing to the development of groundbreaking pharmaceutical products.

Conclusion

Roger Crystal's work in nasal drug delivery represents a significant advancement in the treatment of opioid overdose, showcasing his commitment to improving health outcomes through innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…